Adagio Therapeutics Partners with Biocon Biologics to Bring Potent and Broadly Neutralizing COVID-19 Antibody Treatment to Patients in India and Select Emerging Markets
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced a partnership agreement with Biocon Biologics Ltd., to combat the ongoing COVID-19 crisis in southern Asia. Biocon Biologics Ltd. is a fully integrated biosimilars company and a subsidiary of Biocon Ltd., a global biopharmaceuticals company, (BSE code: 532523, NSE: BIOCON). Under the terms of the agreement, Adagio will provide Biocon with materials and know-how to manufacture and commercialize an antibody treatment based on ADG20 in India and additional select emerging markets.
ADG20, Adagio’s lead product candidate, is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 as either a single or combination agent. Unlike other antibody-based therapies specifically targeting SARS-CoV-2, ADG20 has demonstrated an ability to neutralize SARS-CoV-2 in non-clinical studies, including variants of concern, as well as a broad range of other SARS-like viruses. ADG20 is currently being evaluated in two separate Phase 2/3 global clinical trials, the STAMP trial to evaluate ADG20 for the treatment of non-hospitalized COVID-19 patients and the EVADE trial to evaluate ADG20 for the prevention of COVID-19.
“This partnership underscores the commitment of two companies to come together in order to make a significant impact on global health,” said Tillman Gerngross, Ph.D., co-founder and chief executive officer of Adagio. “At Adagio, we spent a lot of time engineering a highly differentiated molecule in our global fight against COVID-19, and, from the beginning, our metric of success was focused on how many lives we can touch. We expect this partnership to rank very highly on the ‘lives touched’ scale, which was the driver behind pursuing this agreement. Importantly, Biocon’s extensive manufacturing capabilities will enable large scale production, making this potentially life-saving drug broadly available to millions of people who otherwise would not have access to this type of therapy.”
“Earlier this year, we witnessed one of the worst human tragedies in India and southern Asia as a result of COVID-19,” said Kiran Mazumdar-Shaw, executive chairperson of Biocon. “As a company, it is our belief that the pharmaceuticals industry has a humanitarian responsibility to serve patients who are in need. We had looked at dozens of potential molecules, and upon reviewing the ADG20 data, we were convinced this was a differentiated antibody with the potential to address not only today’s virus and variants, but future SARS-like viruses as well. It has become clear that this virus has endemic potential, and Adagio is the ideal partner to significantly help global efforts to both treat and prevent COVID-19. We aim to move quickly to commercialize an antibody that is effective, safe and, most importantly, affordable to millions of people in need.”
The partnership provides Biocon rights to manufacture and commercialize an antibody treatment in India and additional select emerging markets based on the commercial process developed for ADG20. As part of the agreement, Biocon will be granted access to the data from Adagio’s ongoing Phase 2/3 ADG20 clinical trials and access to its anticipated Emergency Use Authorization package, as well as regulatory submissions, to support approval or emergency authorization in India and other select emerging markets. Financial details of the agreement are not disclosed.
ADG20, a monoclonal antibody targeting SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed to be a potent, long-lasting and broadly neutralizing antibody for both treatment and prevention against SARS-CoV-2 and additional clade 1 sarbecoviruses by targeting a highly conserved epitope in the receptor binding domain. In preclinical studies, ADG20 demonstrated broad neutralizing activity against the original SARS-CoV-2 strain as well as known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is formulated at a high concentration, enabling intramuscular administration, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.
About Adagio Therapeutics
Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Dan Budwick, 1AB
Monique Allaire, THRUST Strategic Communications
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-1924.9.2021 14:00:00 EEST | Press release
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that an independent Data Safety Monitoring Board (DSMB) has completed its prespecified interim analysis data review of the safety and efficacy of SAB-185 in the Phase 2 portion of the ACTIV-2 trial and has recommended advancement to Phase 3. SAB-185 is a fully-human, specifically-targeted, broadly-neutralizing polyclonal antibody therapeutic candidate for the treatment of non-hospitalized patients with mild to moderate COVID-19. It is being assessed in the ACTIV-2 trial funded and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH) in collaboration with the AIDS Clinical Trials Group. SAB-185 is advancing to the Phase 3 trial based on meeting pre-defined graduation crite
NTHU Researchers Develop Ultrasonic Vortex Thrombolytic Device24.9.2021 12:00:00 EEST | Press release
As COVID-19 vaccination has raised the issue of thrombosis, Dr. Chih-Kuang Yeh, Distinguished Professor of the Department of Biomedical Engineering and Environmental Sciences, has led a research team to developed the world's first ultrasonic vortex thrombolytic device and to treat thrombosis quickly and safely. The research has been published in Proceedings of the National Academy of Sciences (PNAS) in 2021. Moreover, U.S. and EU patents are granted, with more applications on the way. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210924005015/en/ (Photo: National Tsing Hua University) The device is developed to solve two common thrombosis called pulmonary embolism (PE) and deep vein thrombosis (DVT), which have global prevalence of 10 million new cases annually. DVT is the main cause of PE, and PE can cause heart failure and has mortality rate up to 65%. Professor Yeh explained that the current treatment options includes dr
Long-Term CRYSVITA® ▼ (burosumab) Treatment Reduces the Burden of Disease in Adults With X-Linked Hypophosphataemia (XLH), a Rare Genetic Metabolic Bone Disease24.9.2021 11:00:00 EEST | Press release
Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin) today announced the publication of new data highlighting the sustained benefits of treatment with CRYSVITA® (burosumab) in adults with X-linked hypophosphataemia (XLH), a rare genetic metabolic bone disease. The data show that adults with XLH experience substantial pain, stiffness, fatigue and impairment in physical and ambulatory function. Treatment with CRYSVITA was associated with a significant improvement from baseline after 96 weeks.1 The data are from a randomised, double-blind, placebo-controlled, phase 3 study with an open-label extension to assess the efficacy and safety of CRYSVITA in adults with XLH.2 The study met its primary endpoint, showing a statistically significant effect in increasing serum phosphorus concentrations at 24 weeks, compared to placebo.3 After 24 weeks, all patients were switched to CRYSVITA treatment and data was collected on metabolic and biochemical markers, patient reported outcomes (PROs) and measures of
XPeng Backed HT Aero Unveils Flying Vehicle City Usage Scenarios24.9.2021 08:58:00 EEST | Press release
HT Aero, an urban air mobility (UAM) company in which XPeng Inc. is an investor, today unveiled future urban usage scenarios for its fifth-generation flying vehicle XPeng X2 ("X2"), including autonomous flight take-off and landing for specific city scenarios, back-end scheduling, charging and flight control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923006034/en/ XPeng X2 flying vehicle (Photo: Business Wire) XPeng X2 will present at the 13th Airshow China 2021, starting on September 28 in Zhuhai, Guangdong Province. X2 is equipped with a robust, highly intelligent flight control system and superior autonomous flying capability, able to conduct autonomous flight route planning, all-round real-time imaging, real-time flight monitoring, two-way real-time communications, all-round environmental perception and autonomous return and landing. It is powered by a highly efficient and convenient charging system, leveraging XP
Valbiotis Consolidates Its Development of Innovative Natural Health Solutions by Integrating the Exploration of Microalgae Produced in New Caledonia, Through an Exclusive Agreement With ADECAL-Technopole and IFREMER24.9.2021 08:35:00 EEST | Press release
Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a French research and development company committed to scientific innovation for preventing and combating of metabolic diseases, announces the consolidation of its development of innovative natural health solutions, by integrating the exploration of microalgae produced in New Caledonia, through an exclusive agreement with ADECAL-Technopole and IFREMER. This program should allow to develop a bank of high-potential strains selected by ADECAL-Technopole and IFREMER since 2013 in New Caledonia as part of the "AMICAL" joint research project. Valbiotis will carry out the work necessary to demonstrate the health benefits of these microalgae strains at its preclinical platform in Riom, with a view to filing new patents. Once this scientific validation has been achieved, production will be ensured in New Caledonia for the industrial scale-up, thanks to existing and operational pilot infrastructure for which the technology and
Illumination and Nintendo Announce Theatrical Release Date and Voice Cast for the Super Mario Bros. Animated Film24.9.2021 02:46:00 EEST | Press release
Illumination (HQ: Santa Monica, CA, USA; Founder and CEO: Chris Meledandri) and Nintendo Co., Ltd. (HQ: Kyoto, Minami-ku, Japan; Representative Director and President: Shuntaro Furukawa, “Nintendo” hereafter) today announced that their new animated film based on the world of Super Mario Bros. will be released worldwide during the 2022 holiday season. Universal Pictures will release the film in North America on December 21, 2022, with the release schedule for additional countries and regions to be announced at a future date. The film will be co-financed by Universal Pictures and Nintendo. In addition, the two companies announced the voice actors for the characters Mario (Chris Pratt), Princess Peach (Anya Taylor-Joy), Luigi (Charlie Day), Bowser (Jack Black), Toad (Keegan-Michael Key), Donkey Kong (Seth Rogen), Cranky Kong (Fred Armisen), Kamek (Kevin Michael Richardson) and Spike (Sebastian Maniscalco). Each voice actor was cast for their ability to capture the unique spirit of their c
NuScale Power Signs Memorandum of Understanding with Getka and UNIMOT to Explore SMR Deployment in Poland23.9.2021 20:00:00 EEST | Press release
NuScale Power, Getka Group (Getka) and UNIMOT S.A. (UNIMOT) announced today the three companies have signed a Memorandum of Understanding (MOU) with business purposes including to explore the deployment of NuScale’s small modular reactor (SMR) technology as a coal repurposing solution for existing coal-fired power plants in Poland. Getka is an Oklahoma-based integrated energy company providing construction, and delivery of petroleum, refined products, and alternative energy. Through its Zero Impact Strategy, Getka is focused on reducing emissions output through renewable energy. UNIMOT is a Poland-based multi-energy Capital Group that offers its wholesale and retail customers fuel products, gas and electricity, including renewable energy. This agreement demonstrates the value of international partnership and collaboration in utilizing NuScale’s SMR technology to repurpose coal plants across the country. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom